Antibiotics for the empirical treatment of acute infectious diarrhea in children

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 3, 2006, Pages 217-227

  Diniz Santos, Daniel R ^a,b   Silva, Luciana R ^a   Silva, Nanci ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Antibiotics; Children; Diarrhea; Treatment

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BICOZAMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN STEARATE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NALIDIXIC ACID; OFLOXACIN; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ACUTE DIARRHEA; ANTIBIOTIC RESISTANCE; APLASTIC ANEMIA; ARTHROPATHY; BACTERIAL STRAIN; BONE GROWTH; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; ENAMEL HYPOPLASIA; GROWTH DISORDER; HUMAN; HYDRATION; INFECTIOUS DIARRHEA; MUSCULOSKELETAL DISEASE; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; TOOTH DISCOLORATION; TRAVELLER DIARRHEA;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CHILD; DIARRHEA; HUMANS; VIRUS DISEASES;

EID: 33749060664     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000300011     Document Type: Review

References (141)

1. Kosek M., Bern C., Guerrant R.L. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003;81:197-204.
2. Bern C., Martines J., de Zoysa I., Glass R.I. The magnitude of the global problem of diarrhoeal disease: A ten-year update. Bull World Health Organ 1992;70:705-14.
3. World Health Organization. The management of bloody diarrhoea in young children. WHO, Geneva, Swizterland, 1994 (WHO/CDD/94.49).
4. Goodman L, Segreti J. Infectious diarrhea. Dis Mon 1999;45:268-99.
5. Carneiro N.B., Diniz-Santos D.R., Fagundes S.Q., et al. Clinical and epidemiological aspects of children hospitalized with severe rotavirus-associated gastroenteritis in Salvador, BA, Brazil. Braz J Infect Dis 2005;9:525-8.
6. Karadag A., Acikgoz Z.C., Avci Z., et al. Childhood diarrhoea in Ankara, Turkey: epidemiological and clinical features of rotavirus-positive versus rotavirus-negative cases. Scand J Infect Dis 2005;37:269-75.
7. Zhang X., McDaniel A., Wolf L., et al. Quinolone antibiotics induce shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000;181:664-70.
8. Wong C.S., Jelacic S., Habeeb R.L., et al. The risk of hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-6.
9. Pal SC. Epidemic bacillary dysentery in West Bengal, India, 1984. Lancet 1984;1:1462.
10. Bennish M., Eusof A., Kay B., Wierzba T. Multiresistant Shigella infections in Bangladesh. Lancet 1985;2:441.
11. Sen D., Sengupta P.G., Bhattacharya S.K., et al. Epidemic Shiga bacillus dysentery in Port Blair, Andaman and Nicobar Islands, India. J Diarrhoeal Dis Res 1986;4:161-2.
12. Lolekha S., Vibulbandhitkit S., Poonyarit P. Response to antimicrobial therapy for shigellosis in Tahiland. Rev Infect Dis 1991;13(suppl 4):S342-6.
13. Frost J.A., Willshaw G.A., Berclay E.A., et al. Plasmid characterization of drug-resistant Shigella dysenteriae 1 from an epidemic in Central Africa. J Hyg 1985;94:163-72.
14. Mates A., Eyny D., Philo S. Antimicrobial resistance trends in Shigella serogroups isolated in Israel, 1990-1995. Eur J Clin Microbiol Infect Dis 2000;19:108-11.
15. Centers for Disease Control. Multiply resistant shigellosis in a day-care center - Texas. MMWR 1986;35:753-5.
16. Centers for Disease Control. Nationwide dissemination of multiply resistant Shigella sonnei following a common-source outbreak. MMWR 1987;36:633-4.
17. Centers for Disease Control. Shigella dysenteriae type 1 - Guatemala, 1991. MMWR 1991;40:421-8.
18. Bratoeva M.P., John J.F., Jr. Dissemination of trimethoprim-resistant clones of Shigella sonnei in Bulgaria. J Infect Dis 1989;159:648-53.
19. Bennish M.L., Salam M.A., Hossain H.A., et al. Antimicrobial resistance to Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulphametoxazole and nalidixic acid. Clin Infect Dis 1992;14:1055-60.
20. Diniz-Santos D.R., Santana J.S., Barretto J.R., et al. Epidemiological and microbiological aspects of acute bacterial diarrhea in children from Salvador, Bahia, Brazil. Braz J Infect Dis 2005;9:75-81.
21. Aysev A.D., Guriz H. Drug resistance of Shigella strains isolated in Ankara, Turkey, 1993-1996. Scand J Infect Dis 1998;30:351-3.
22. Egah D.Z., Banwat E.B., Audu E.S., et al. Multiple drug resistant strains of Shigella isolated in Jos, central Nigeria. Niger Postgrad Med J 2003;10:154-6.
23. Anh N.T., Cam P.D., Dalsgaard A. Antimicrobial resistance of Shigella spp. isolated from diarrheal patients between 1989 and 1998 in Vietnam. Southeast Asian J Trop Med Public Health 2001;32:856-62.
24. Lima A.A., Lima N.L., Pinho M.C., et al. High frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in northeastern Brazil during the period 1988 to 1993. Antimicrob Agents Chemother 1995;39:256-9.
25. Putnam S.D., Riddle M.S., Wierzba T.A., et al. Antimicrobial susceptibility trends among Escherichia coli and Shigella spp. isolated from rural Egyptian paediatric populations with diarrhoea between 1995 and 2000. Clin Microbiol Infect 2004;10:804-10.
26. Ko W.C., Yu K.W., Liu C.Y., et al. Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan. Antimicrob Agents Chemother 1996;40:1260-2.
27. Pai C., Gillis F., Tuomanen E., Marks M.I. Placebo controlled double-blind evaluation of trimethoprim-sulfamethoxazole treatment of Yersinia enterocolitica gastroenteritis. J Pediatr 1984;104:308-11.
28. Marks M.I., Pai C.H., Lafleur L., et al. Yersinia enterocolitica gastroenteritis: a prospective study of clinical, bacteriologic, and epidemiologic features. J Pediatr 1980;96:26-31.
29. Black R.E. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 1990;12(Suppl1):S73-9.
30. Gangarosa E.J., Bennett J.V., Wyatt C., et al. An epidemic-associated episome? J Infect Dis 1972;126:215-8.
31. Butler T., Linh N.N., Arnold K., Pollack M. Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor. Lancet 1973;2:983-5.
32. Kamili M.A., Ali G., Shah S.Y., et al. Multiple drug resistant typhoid fever outbreak in Kashmir Valley. Indian J Med Sci 1993;47:147-51.
33. Anand A.C. The anatomy of an epidemic (the final report on an epidemic of multidrug resistant enteric fever in eastern India). Trop Gastroenterol 1993;14:21-7.
34. Uwaydah A.K., Matar I., Chacko K.C., Davidson J.C. The emergence of antimicrobial resistant Salmonella typhi in Qatar: epidemiology and therapeutic implications. Trans R Soc Trop Med Hyg 1991;85:790-2.
35. Sood S., Kapil A., Das B., et al. Re-emergence of chloramphenicol-sensitive Salmonella typhi. Lancet 1999;353:1241-2.
36. Chandra J., Marwaha R.K., Sachdeva S. Chloramphenicol-resistant Salmonella typhi: therapeutic considerations. Indian J Pediatr 1984;51:567-70.
37. West B.C., Devault G.A. Jr., Clement J.C., Williams D.M. Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine. Rev Infect Dis 1988;10:1048-51.
38. Abbas Z., Malik I., Khan A. Sequential induction of aplastic anemia and acute leukemia by chloramphenicol. J Pak Med Assoc 1993;43:58-9.
39. Salam M.A., Bennish M.L. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic-acid in childhood shigellosis. J Pediatr 1988;113:901-7.
40. Bhattacharya S.K., Datta P., Datta D., et al. Relative efficacy of trimethoprim-sulfamethoxazole and nalidixic acid for acute invasive diarrhea. Antimicrob Agents Chemother 1987;31:837.
41. Munshi M.H., Sack D.A., Haider K., et al. Plasmid-mediated resistance to nalidixic-acid in Shigella dysenteriae type 1. Lancet 1987;2:419-21.
42. Dagan D., Orr N., Yavzori M., et al. Retrospective analysis of the first clonal outbreak of nalidixic acid-resistant Shigella sonnei shigellosis in Israel. Eur J Clin Microbiol Infect Dis 2002;21:887-9.
43. Ghosh A.R., Sugunan A.P., Sehgal S.C., Bharadwaj A.P. Emergence of nalidixic acid-resistant Shigella sonnei in acute-diarrhea patients on Andaman and Nicobar Islands, India. Antimicrob Agents Chemother 2003;47:1483.
44. Cheasty T., Day M., Threlfall E.J. Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy. Clin Microbiol Infect 2004;10:1033-5.
45. Panhotra B.R., Saxena A.K., Al-Mulhim K. Emergence of nalidixic acid resistance in Shigella sonnei isolated from patients having acute diarrheal disease: report from Eastern Province of Saudi Arabia. Jpn J Infect Dis 2004;57:116-8.
46. Panhotra B.R., Saxena A.K., Al-Ghamdi A.M. Emerging nalidixic acid and ciprofloxacin resistance in non-typhoidal Salmonella isolated from patients having acute diarrhoeal disease. Ann Saudi Med 2004;24:332-6.
47. Parry C.M., Wain J., Chinh N.T., et al. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998;351:1289.
48. Murphy T.M., McNamara E., Hill M., et al. Epidemiological studies of human and animal Salmonella typhimurium DT104 and DT104b isolated in Ireland. Epidemiol Infect 2001;126:3-9.
49. Gorman R., Adley C.C. Nalidixic acid-resistant strains of Salmonella showing decreased susceptibility to fluoroquinolones in the mid-west region of the Republic of Ireland. J Antimicrob Chemother 2003;51:1047-9.
50. Mahmood A. Nalidixic acid is still the drug of choice for shigellosis in Pakistan. J Pak Med Assoc 2001;51:101.
51. MoezArdalan K., Zali M.R., Dallal M.M., et al. Prevalence and pattern of antimicrobial resistance of Shigella species among patients with acute diarrhoea in Karaj, Tehran, Iran. J Health Popul Nutr 2003;21:96-102.
52. Alam A.N., Islam M.R., Hossain M.S., et al. Comparison of pivmecillinam and nalidixic acid in the treatment of acute shigellosis in children. Scand J Gastroenterol 1994;29:313-7.
53. Bouissou H., Caujolle D., Caujolle F., Milhaud G. Tissus cartilagineux et acide nalidixique. C R Acad Sc Paris 1978;23:1743-6.
54. Brand H.S., van Kampen G.P., van der Korst J.K. Effect of nalidixic acid, pipemidic acid and cinoxacin on chondrocyte metabolism in explants of articular cartilage. Clin Exp Rheumatol 1990;8:393-5.
55. Nuutinen M., Turtinen J., Uhari M. Growth and joint symptoms in children treated with nalidixic acid. Pediatr Infect Dis J 1994;13:798-800.
56. Schaad U.B., Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987;15:165-8.
57. Hirose K, Terajima J, Izumiya H, et al. Antimicrobial susceptibility of Shigella sonnei isolates in Japan and molecular analysis of S. sonnei isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2005;49:1203-5.
58. Albayrak F., Cokca F., Erdem B., Aysev A.D. Predictive value of nalidixic acid resistance for detecting salmonellae with decreased ciprofloxacin susceptibility. Int J Antimicrob Agents 2004;23:332-6.
59. Anjum P., Qureshi A.H., Rafi S. Fluoroquinolone resistance in typhoidal Salmonella and its detection by nalidixic acid disc diffusion. J Pak Med Assoc 2004;54:295-301.
60. Asna S.M., Haq J.A., Rahman M.M. Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 2003;56:32-3.
61. Kapil A., Das B. Nalidixic acid susceptibility test to screen ciprofloxacin resistance in Salmonella typhi. Indian J Med Res 2002;115:49-54.
62. Oteo J., Aracil B., Alos J.I., Gomes-Garcez J.L. High rate of resistance to nalidixic acid in Salmonella enterica: its role as a marker of resistance to fluoroquinolones. Clin Microbiol Infect 2000;6:273-6.
63. Hakanen A., Kotilainen P., Jalava J., et al. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999;37:3572-7.
64. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: ninth informational (suppl.). Approved Standard M100-S9. Villanova, PA: National Committee for Clinical Laboratory Standards, 1999.
65. Hopper D.C., Wolfson J.S. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94.
66. Akalin H.E. Quinolones in the treatment of acute bacterial diarrhoeal diseases. Drugs 1993;45(Suppl 3):114-8.
67. Pichler H.E., Diridl G., Stickler K., Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 1987;82:329-32.
68. Pichler H.E., Diridl G, Wolf D. Ciprofloxacin in the treatment of acute bacterial diarrhea: a double-blind study. Eur J Clin Microbiol 1986;5:241-3.
69. Goodman L.J., Trenholme G.M., Kaplan R.L., et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990;150:541-6.
70. Dryden M.S., Gabb R.J., Wright S.K. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996;22:1019-25.
71. Wistrom J., Jertborn M., Ekwall E., et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med 1992;117:202-8.
72. Bennish M.L., Salam M.A., Kahn W.A., et al. Treatment of shigellosis: III. Comparison of one and two dose ciprofloxacin with standard 5 day treatment. A randomized, blinded trial. Ann Inter Med 1992;117:727-34.
73. Guyon P., Cassel-Beraud A.M., Rakotonirina G, Gendrel D. Short treatment with pefloxacin in Madagascan children with shigellosis due to multiresistant organisms. Clin Infect Dis 1994;19:1172-3.
74. Gendrel D., Moreno J.L., Nduwimana M., et al. One-dose treatment with pefloxacin for infection with multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin Infect Dis 1997;24:83.
75. Hakanen A., Siitonen A., Kotilainen P., Huovinen P. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997. J Antimicrob Chemother 1999;43:145-8.
76. Molbak K., Baggesen D.L., Aarestrup F.M., et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N Engl J Med 1999;349:1420-5.
77. Dutta S., Dutta P., Matsushita S., et al. Shigella dysenteriae serotype 1, Kolkata, India. Emerg Infect Dis 2003;9:1471-4.
78. Nakaya H., Yasuhara A., Yoshimura K., et al. Life-threatening infantile diarrhea from fluoroquinolone-resistant Salmonella enterica typhimurium with mutations in both gyrA and parC. Emerg Infect Dis 2003;9:255-7.
79. Hoge C.W., Gambel J.M., Srijan A., et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998;26:341-5.
80. Hakanen A., Jousimies-Somer H., Siitonen A., et al. Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination. Emerg Infect Dis 2003;9:267-70.
81. Black A., Redmond A.O., Steen H.I., Oborska I.T., Tolerance and safety of ciprofloxacin in pediatric patients. J Antimicrob Chemother 1990;26:25-9.
82. Hampel B., Hullmann R., Schmidt H. Ciprofloxacin in paediatrics: worldwide clinical experience based on compassionate use - safety report. Pediatr Infect Dis J 1997;16:127-9.
83. Leibovitz E., Janco J., Piglanski L., et al. Oral ciprofloxacin versus intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 2000;19:1060-7.
84. Ball P., Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995;13:343-58.
85. Rahm V., Schacht P. Safety of ciprofloxacin. A review. Scand J Infect Dis Suppl 1989;60:120-8.
86. Chysky V., Kapila K., Hullmann R., et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991;19:289-96.
87. Chalumeau M., Tonnelier S., d'Athis P., et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter comparative cohort study in France. Pediatrics 2003;111:714-9.
88. American Academy of Pediatrics. Fluoroquinolones. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Groove Village, IL: American Academy of Pediatrics 2003:693-4.
89. Gendrel D., Chalumeau M., Moulin F., Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the commumity? Lancet Infect Dis 2003;3:537-46.
90. Schaad U.B., Abdus-Salam M., Aujard Y., et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy Commission. Pediatr Infect Dis J 1995;14:1-9.
91. Schaad UB. Pediatric use of quinolones. Pediatr Infect Dis J 1999;18:469-70.
92. Aradottir E., Yogev R. the use of fluoroquinolones in pediatrics - a reassessment. Semin Pediatr Infect Dis 1999;10:31-37.
93. Eidlitz-Marcus T., Cohen Y.H., Nussinovitch M., et al. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr 1993;123:822-4.
94. Bhutta Z.A., Khan I.A., Shadmani M. Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob Agents Chemother 2000;44:450-2.
95. Girgis N.I., Sultan Y., Hammad O., Farid Z. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Pediatr Infect Dis J 1995;14:603-5.
96. Lin T.Y., Chiu C.H., Lin P.Y., et al. Short-term ceftriaxone therapy for treatment of severe non-typhoidal Salmonella enterocolitis. Acta Paediatr 2003;92:537-40.
97. Varsano I., Eidlitz-Marcus T., Nussinovitch M., Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 1991;118:627-32.
98. Dutta P., Mitra U., Dutta S., et al. Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J Med Res 2001;113:210-3.
99. Butt T., Ahmad R.N., Mahmood A., Zaidi S. Ciprofloxacin treatment failure in typhoid fever case, Pakistan. Emerg Infect Dis 2003;9:1621-2.
100. Martin J.M., Pitetti R., Maffei F., et al. Treatment of shigellosis with cefixime: two days versus five days. Pediatr Infect Dis J 2000;19:522-6.
101. Salam M.A., Seas C., Khan W.A., Bennish M.L. Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med 1995;123:505-8.
102. Ashkenazi S., Amir J., Waisman Y., et al. Arandomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. J Pediatr 1993;123:817-21.
103. Basualdo W., Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003;22:374-7.
104. Frenck R.W. Jr., Mansour A., Nakhla I., et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 2004;38:951-7.
105. Frenck R.W. Jr., Nakhla I., Sultan Y., et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 2000;31:1134-8.
106. Butler T., Sridhar C.B., Daga M.K., et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 1999;44:243-50.
107. Girgis N.I., Butler T., Frenck R.W., et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 1999;43:1441-4.
108. Chinh N.T., Parry C.M., Ly N.T., et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother 2000;44:1855-9.
109. Adachi J.A., Ericsson C.D., Jiang Z.D., et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003;37:1165-71.
110. Kuschner R.A., Trofa A.F., Thomas R.J., et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995;21:536-41.
111. Anand V., Arora S., Patwari A., et al. Multidrug resistance in Vibrio cholerae. Indian Pediatr 1996;33:774-7.
112. Siddique A.K., Salam M., Islam M.S., et al. Why treatment centers failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet 1995;345:359-61
113. Miron D., Torem M., Merom R., Colodner R. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. Pediatr Infect Dis J 2003;23:367-8.
114. Khan W.A., Seas C., Dhar U., et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Inter Med 1997;126:697-703.
115. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998;27:702-10.
116. Vasa C.V., Glatt A.E. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol 2003;98:354-8.
117. Wenisch C., Parschalk B., Hasenhundl M., et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile diarrhea. Clin Infect Dis 1996;23:813-8.
118. Fekety R. Guidelines for the diagnosis and treatment of Clostridium difficile-associated diarrhea and colitis American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:739-50.
119. Vanhoof R., Coignau H., Stas G., et al. Activity of bicozamycin (CGP 3543/E) on different enteropathogenic microorganisms: comparison with other antimicrobial agents. J Antimicrob Chemother 1982;10:343-6.
120. Ericsson C.D., DuPont H.L., Sullivan P., et al. Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers' diarrhea. Ann Intern Med 1983;98:20-5.
121. Goossens H., DeMol P., Coignau H., et al. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU 28965 (a new macrolide) and other agents against enteropathogens. Antimicrob Agents Chemother 1985;27:388-92.
122. DuPont H.L., Ericsson C.D., Mathewson J.J., et al. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. JAMA 1992;267:1932-5.
123. Steffen R., Sack D.A., Riopel L., et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003;98:1073-8.
124. DuPont H.L., Ericsson C.D., Matthewson J.J., et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 1998;59:708-14.
125. DuPont H.L., Jiang Z.D., Ericsson C.D., et al. Rifaximin versus ciprofloxacin for the treatment of travelers' diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001;33:1807-15.
126. Guarner F., Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39:237-8.
127. Wilson K.H., Perini I. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immunol 1988;56:2610-4.
128. Walker W.A. Role of nutrients and bacterial colonization in the development of intestinal host defense. J Pediatr Gastroenterol Nutr 2000;30(suppl):S2-7.
129. Bernet M.F., Brassart D., Neeser J.R., et al. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bactéria. Gut 1994;35:483-9.
130. Michail S., Abernathy F. Lactobacillus plantarum inhibits the intestinal epithelial migration of neutrophils induced by enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr 2003;36:385-91.
131. Michail S., Abernathy F. Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli infection. J Pediatr Gastroenterol Nutr 2003;35:350-5
132. Szajewska H., Mrukowicz J.Z. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001;33(Suppl 2):S17-25.
133. Van Niel C., Feudtner C., Garrison M.M., Christakis D.A. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002;109:678-84.
134. Huang J.S., Bousvaros A., Lee J.W., et al. Efficacy of probiotic use in acute diarrhea in children. A meta-analysis. Dis Dis Sci 2002;47:2625-34.
135. Hatakka K., Savilahti R., Ponka A., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centers: double-blind randomized trial. BMJ 2001;322:1-5.
136. Szajewska H., Kotowska M., Mrukowicz J.Z., et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001;138:361-5.
137. Szajewska H., Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005;22:365-72.
138. Marteau P.R., de Vrese M., Cellier C.J., et al. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73(suppl):430-6.
139. Chiu C.H., Lin T.Y., Ou J.T. A clinical trial comparing oral azithromycin, cefixime and no antibiotics in the treatment of acute uncomplicated Salmonella enteritis in children. Paediatr Child Health 1999;35:372-4.
140. Sader H.S., Jones R.N., Gales A.C., et al. SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001. Braz J Infect Dis 2004;8:25-79.
141. Oplustil C.P., Nunes R., Mendes C., RESISTNET Group. Multicenter evaluation of resistance patterns of Klebsiella pneumoniae, Escherichia coli, Salmonella spp., and Shigella spp. isolated from clinical specimens in Brazil: RESISTNET surveillance program. Braz J Infect Dis 2001;5:8-12.